Photodynamic and Pharmacologic Treatment of CNV
Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)
  • Phase

    Phase 1/Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.
Study Started
Dec 31
Primary Completion
Jun 30
Study Completion
Jun 30
Last Update
Jul 10

Drug verteporfin (Visudyne)

Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1

  • Other names: Visudyne = verteporfin, Lucentis = ranibizumab

Drug ranibizumab (Lucentis)

ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol

  • Other names: Lucentis = ranibizumab

I Experimental

Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)

II Experimental

Treatment with ranibizumab (Lucentis)


Inclusion Criteria:

All previously untreated CNV secondary to MD
No Results Posted